Health

First drug for delusions in Parkinson's patients approved

Associated Press - WASHINGTON (AP) -- Federal health officials have approved an experimental drug to treat psychotic delusions and behaviors that often afflict patients with Parkinson's disease, the debilitating movement disorder.

The drug from Acadia Pharmaceuticals Inc. is the first drug for the condition, which affects approximately half of Parkinson's patients. An estimated 50,000 Americans are diagnosed with Parkinson's each year, making it the second-most common neurodegenerative disease in the U.S.

The company's drug Nuplazid is part of the antipsychotic family of medications, including Abilify, Zyprexa and Seroquel, which are used to treat schizophrenia and bipolar disorder. Like those drugs, Nuplazid will carry a boxed warning about the risks of death when used in older patients with dementia. The drugs are not approved for that use. Acadia is based in San Diego.

Copyright Associated Press


Editor's Pick

In Case You Missed It

Don't Miss

  • Text Alerts
    Copyright 2018 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

    Text Alerts

    Get breaking news and weather alerts on your cell phone.

    Read More »
  • Email Alerts
    Copyright by WWLP - All rights reserved

    Email Alerts

    Sign up for Breaking News, Weather, Daily News, I-Team and Traffic Alerts emails from 22News.

    Read More »
  • Weather App
    Copyright 2018 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

    Weather App

    The most powerful weather app in western Mass. with personal forecasts, alerts, and radar from the 22News Storm Team.

    Read More »

Latest News - Local

Video Center